Hematologic Oncology

Ruben Mesa, MD, discusses the FDA approval of ropeginterferon alfa-2b-njft, the first new essential thrombocythemia therapy in nearly 30 years.

Ropeginterferon alfa may play an important role in future combination strategies in essential thrombocythemia, said Ruben Mesa, MD, FACP.

The FDA approval of ropeginterferon alfa-2b may lead to longer and better outcomes in essential thrombocythemia, according to Ruben Mesa, MD, FACP.

Data from the phase 3 SENTRY trial support the supplemental new drug application for selinexor plus ruxolitinib in patients with myelofibrosis.

Data from the phase 3 SURPASS ET trial supported the approval of ropeginterferon alfa-2b-njft for those with essential thrombocythemia.

Results from the phase 3 VERIFY trial led to the approval of rusfertide in polycythemia vera.

In a real-world setting, venetoclax plus a hypomethylating agent produced a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia.

Andrew Evens, DO & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across NJ.

The FDA cited outstanding manufacturing observations while raising no concerns about clinical data, bioequivalence, or stability in its CRL.

The phase 2 SANRECO trial met its primary end point, with 88% of this polycythemia vera population achieving a response with divesiran vs 19% with placebo.

Updated results from the phase 2 ELIANA trial support tisa-cel as definitive therapy for pediatric and young adult patients with relapsed/refractory B-ALL.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Transplant-associated thrombotic microangiopathy GVHD are related, but distinct consequences of endothelial injury after allogeneic HCT.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, predicts operational challenges as CAR T-cell therapy expands to non-oncology indications.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, says equitable access to CAR T-cell therapy depends on partnership, not just center certification.

Clinicians “still don’t have the answer” on true toxicity thresholds, says Tiba Al Sagheer, PharmD, BCOP, BCACP, on CAR T-cell toxicity management.

Tiba Al Sagheer, PharmD, BCOP, BCACP, said CAR T-cell expansion signals toxicity risk differently across cilta-cel and ide-cel.

Differentiating between CRS and IEC-HS remains a challenge in mitigating toxicity associated with cellular therapy, said Tiba Al Sagheer, PharmD, BCOP, BCACP.

The world of cellular therapy is “still ever-expanding” as novel constructs continue to emerge, according to Megan Melody, MD.

Megan Melody, MD, says it could be “years” before data clarify how to sequence bispecific antibodies and CAR T-cell therapy.

Megan Melody, MD, says acute CAR T-cell toxicities are well managed, but delayed neurotoxicity remains a challenge.

The approval of Orca-T validates many years of work dedicated to manipulating the graft to improve outcomes among patients undergoing allogeneic transplant.

Orca-T is a “big advance” that must be studied further among patients with acute leukemias and myelodysplastic syndromes.

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.